Genesystem Co. Ltd.
Genesystem Co., Ltd., a biotech engineering company, specializes in molecular testing solutions to target on-site testing needs. The company offers PCR systems, multiplex biochips, and PCR reagents. It also provides human pathogen assays, including novel coronavirus (SARS-CoV-2) detection kits, SARS-CoV-2/Flu/RSV simultaneous detection kits, and mycobacterium tuberculosis detection kits; veterina… Read more
Genesystem Co. Ltd. (363250) - Total Assets
Latest total assets as of September 2025: ₩23.55 Billion KRW
Based on the latest financial reports, Genesystem Co. Ltd. (363250) holds total assets worth ₩23.55 Billion KRW as of September 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Genesystem Co. Ltd. - Total Assets Trend (2018–2024)
This chart illustrates how Genesystem Co. Ltd.’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Genesystem Co. Ltd. - Asset Composition Analysis
Current Asset Composition (December 2024)
Genesystem Co. Ltd.'s total assets of ₩23.55 Billion consist of 33.4% current assets and 66.6% non-current assets.
| Asset Category | Amount (KRW) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | ₩5.62 Billion | 18.8% |
| Accounts Receivable | ₩87.93 Million | 0.3% |
| Inventory | ₩1.95 Billion | 6.5% |
| Property, Plant & Equipment | ₩8.65 Billion | 28.9% |
| Intangible Assets | ₩6.59 Billion | 22.1% |
| Goodwill | ₩283.12 Million | 1.0% |
Asset Composition Trend (2018–2024)
This chart illustrates how Genesystem Co. Ltd.'s asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Genesystem Co. Ltd.'s current assets represent 33.4% of total assets in 2024, a decrease from 86.5% in 2018.
- Cash Position: Cash and equivalents constituted 18.8% of total assets in 2024, down from 77.3% in 2018.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 22.0% of total assets, an increase from 8.0% in 2018.
- Asset Diversification: The largest asset category is property, plant & equipment at 28.9% of total assets.
Genesystem Co. Ltd. Competitors by Total Assets
Key competitors of Genesystem Co. Ltd. based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
ADCNF
OTCGREY:ADCNF
|
USA | $4.51 Billion |
|
Berry Genomics Co Ltd
SHE:000710
|
China | CN¥2.34 Billion |
|
Malaysian Genomics Resource
KLSE:0155
|
Malaysia | RM20.70 Million |
|
NSN Co. Ltd
KQ:031860
|
Korea | ₩60.96 Billion |
|
JOONGANG DNM Co.Ltd
KQ:051980
|
Korea | ₩121.79 Billion |
|
GeneMatrix Inc
KQ:109820
|
Korea | ₩28.03 Billion |
|
Genoray Co. Ltd
KQ:122310
|
Korea | ₩125.67 Billion |
|
Green Cross Lab Cell Corporation
KQ:144510
|
Korea | ₩565.79 Billion |
Genesystem Co. Ltd. - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Lower asset utilization - Genesystem Co. Ltd. generates 0.04x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Negative ROA - Genesystem Co. Ltd. is currently not profitable relative to its asset base.
Genesystem Co. Ltd. - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 2.24 | 6.39 | 4.28 |
| Quick Ratio | 1.49 | 4.99 | 3.78 |
| Cash Ratio | 0.00 | 3.89 | 0.00 |
| Working Capital | ₩3.08 Billion | ₩ 10.96 Billion | ₩ 8.74 Billion |
Genesystem Co. Ltd. - Advanced Valuation Insights
This section examines the relationship between Genesystem Co. Ltd.'s asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 2.51 |
| Latest Market Cap to Assets Ratio | 0.00 |
| Asset Growth Rate (YoY) | -23.2% |
| Total Assets | ₩29.90 Billion |
| Market Capitalization | $21.22 Million USD |
Valuation Analysis
Below Book Valuation: The market values Genesystem Co. Ltd.'s assets below their book value (0.00 x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: Genesystem Co. Ltd.'s assets decreased by 23.2% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Genesystem Co. Ltd. (2018–2024)
The table below shows the annual total assets of Genesystem Co. Ltd. from 2018 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | ₩29.90 Billion | -23.19% |
| 2023-12-31 | ₩38.93 Billion | -5.48% |
| 2022-12-31 | ₩41.18 Billion | -18.70% |
| 2021-12-31 | ₩50.66 Billion | +167.76% |
| 2020-12-31 | ₩18.92 Billion | +828.48% |
| 2019-12-31 | ₩2.04 Billion | -50.99% |
| 2018-12-31 | ₩4.16 Billion | -- |